GW to launch Epidiolex in U.S. following DEA reschedule

GW Pharmaceuticals plc (NASDAQ:GWPH) said the U.S. Drug Enforcement Agency has rescheduled Epidiolex cannabidiol to schedule V, the lowest restriction classification, from a schedule I, clearing the way for GW to launch the drug in the U.S. The company hopes to launch Epidiolex, the first FDA approved marijuana-derived purified substance, within six weeks.

FDA approved Epidiolex in June to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients ages two and older (see “FDA Approves GW’s Epidiolex, First Marijuana-Derived Drug”)...